# A Bridging Study of the SYN023 on Healthy Adult Subjects

> **NCT04495569** · PHASE1,PHASE2 · COMPLETED · sponsor: **Synermore Biologics (Suzhou) Co., Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Communicable Disease Transmission
- Zoonotic Disease
- Rabies Human
- Vaccine Reaction
- Immunisation Reaction

## Interventions

- **BIOLOGICAL:** recombinant anti-rabies human monoclonal antibody injection (SYN023)
- **BIOLOGICAL:** Rabies Vaccine

## Key facts

- **NCT ID:** NCT04495569
- **Lead sponsor:** Synermore Biologics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-26
- **Primary completion:** 2019-06-20
- **Final completion:** 2020-02-20
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04495569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04495569, "A Bridging Study of the SYN023 on Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04495569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*